Detalhe da pesquisa
1.
Identification of miRSNPs associated with the risk of multiple myeloma.
Int J Cancer
; 140(3): 526-534, 2017 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27718532
2.
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Lancet Haematol
; 10(10): e801-e812, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37793771